No CrossRef data available.
Article contents
Prevalence of metabolic syndrome and of symptoms of anxiety and depression in patients undergoing colonoscopy
Published online by Cambridge University Press: 23 March 2020
Abstract
Metabolic syndrome (MetS) is defined by metabolic and cardio-vascular impairments and is frequently associated with anxiety and depressive disorders. Both MetS and anxiety-depressive syndromes feature similar systemic inflammatory alterations. Inflammation of the large bowel is also a key factor for the development of colorectal cancer (CRC).
To measure the prevalence of MetS and symptoms of anxiety and depression among patients undergoing colonoscopy.
Cross-sectional study. Patients undergoing colonoscopy aged 40 or more, with negative history for neoplasia or inflammatory bowel disease, were enrolled. Data collected: colonoscopy outcome, presence/absence of MetS (IDF and ATP III criteria), presence/absence of depressive and anxiety symptoms assessed with HADS.
The sample was made up of 53 patients (female 24, 45.3%). Mean age was 60.66 ± 9.08. At least one adenoma was found to 23 patients (43.3%). Prevalence of MetS ranged from 34% to 36% (ATP III and IDF criteria, respectively). Prevalence of depressive and anxiety symptoms was 20% and 33%, respectively.
Prevalence of MetS, anxiety and depressive symptoms among patients undergoing colonoscopy was higher than in the general population.
The authors have not supplied their declaration of competing interest.
- Type
- e-Poster Walk: Consultation liaison psychiatry and psychosomatics - Part 2
- Information
- European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S318 - S319
- Copyright
- Copyright © European Psychiatric Association 2017
Comments
No Comments have been published for this article.